Patents by Inventor Wayne D. Crill

Wayne D. Crill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
    Patent number: 11154608
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: October 26, 2021
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES
    Publication number: 20200147201
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 14, 2020
    Applicant: The Government of the U.S.A. as rep. by the Secretary of the Dept. of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
    Patent number: 10568956
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 25, 2020
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES
    Publication number: 20180353593
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Applicant: The Govt. of the U.S.A. as rep. by the Secretary of the Dept. of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
    Patent number: 10092637
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 9, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
    Patent number: 9650422
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: May 16, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES
    Publication number: 20160375123
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: The Government of the U.S.A. as rep. by the Secretary of the Department of Health and Human Se
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • LOCALIZATION AND CHARACTERIZATION OF FLAVIVIRUS ENVELOPE GLYCOPROTEIN CROSS-REACTIVE EPITOPES AND METHODS FOR THEIR USE
    Publication number: 20150246951
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Application
    Filed: March 16, 2015
    Publication date: September 3, 2015
    Applicant: The Government of the USA as represented by the Secretary of the Dept.of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
    Patent number: 9000141
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 7, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES
    Publication number: 20140286983
    Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
    Type: Application
    Filed: October 18, 2012
    Publication date: September 25, 2014
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
  • Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
    Patent number: 7906292
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glyco-protein cross-reactive epitopes and flavivirus E-glycoprotein crossreactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: March 15, 2011
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • LOCALIZATION AND CHARACTERIZATION OF FLAVIVIRUS ENVELOPE GLYCOPROTEIN CROSS-REACTIVE EPITOPES AND METHODS FOR THEIR USE
    Publication number: 20110059131
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 10, 2011
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Localization and Characterization of Flavivirus Envelope Gylcoprotein Cross-Reactive Epitopes and Methods for their Use
    Publication number: 20080248064
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glyco-protein cross-reactive epitopes and flavivirus E-glycoprotein crossreactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Application
    Filed: July 27, 2005
    Publication date: October 9, 2008
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill